Zoetis Inc. is a leading animal health company with a market cap of $56.3 billion, known for its medicines, vaccines, and health solutions for livestock and companion animals. Despite a 27.5% decrease in shares over the past year, YTD gains of 1.3% have been noted. The company has faced challenges due to safety concerns and slowing sales of key drugs, contributing to weaker growth. However, analysts expect a 7.1% increase in EPS for 2025. The consensus rating is a “Moderate Buy,” though recent downgrades have occurred, with Piper Sandler analyst David Westenberg lowering the price target to $135.

Read more at Yahoo Finance: Do Wall Street Analysts Like Zoetis Stock?